Study of Eculizumab in Patients with GMG
ID Number 08-1294Principal Investigator(s)
Mark A. Sivak
Department(s) or Division(s)
The purpose of this study is to evaluate the safety of the drug eculizumab in a randomized, double-blind, placebo-controlled cross-over trial of patients with generalized Myasthenia Gravis (MG) who have not responded to other MG treatments.
Recruiting Patients: Yes